Free Trial
NASDAQ:KTTA

Pasithea Therapeutics (KTTA) Stock Price, News & Analysis

Pasithea Therapeutics logo
$0.71 -0.01 (-1.67%)
As of 03:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Pasithea Therapeutics Stock (NASDAQ:KTTA)

Key Stats

Today's Range
$0.68
$0.73
50-Day Range
$0.69
$0.97
52-Week Range
$0.65
$7.50
Volume
74,896 shs
Average Volume
3.17 million shs
Market Capitalization
$5.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pasithea Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

KTTA MarketRank™: 

Pasithea Therapeutics scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Pasithea Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pasithea Therapeutics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pasithea Therapeutics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pasithea Therapeutics has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Pasithea Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.97% of the float of Pasithea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Pasithea Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pasithea Therapeutics has recently decreased by 13.29%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Pasithea Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Pasithea Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.97% of the float of Pasithea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Pasithea Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pasithea Therapeutics has recently decreased by 13.29%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Pasithea Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Pasithea Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $787.00 in company stock.

  • Percentage Held by Insiders

    Only 2.70% of the stock of Pasithea Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 23.92% of the stock of Pasithea Therapeutics is held by institutions.

  • Read more about Pasithea Therapeutics' insider trading history.
Receive KTTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KTTA Stock News Headlines

Pasithea Therapeutics (NASDAQ:KTTA) Stock Price Up 2.6% - What's Next?
Your blueprint for crypto wealth
Mark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…
KTTA Pasithea Therapeutics Corp. - Seeking Alpha
See More Headlines

KTTA Stock Analysis - Frequently Asked Questions

Pasithea Therapeutics' stock was trading at $3.15 at the start of the year. Since then, KTTA shares have decreased by 77.6% and is now trading at $0.7050.

Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced its earnings results on Thursday, May, 15th. The company reported ($1.61) earnings per share for the quarter.

Shares of Pasithea Therapeutics reverse split on the morning of Tuesday, January 2nd 2024.The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Pasithea Therapeutics (KTTA) raised $17 million in an initial public offering on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share.

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pasithea Therapeutics investors own include Biofrontera (BFRI), Meta Platforms (META), Plug Power (PLUG), QuantumScape (QS), Airbnb (ABNB), Advanced Micro Devices (AMD) and Ginkgo Bioworks (DNA).

Company Calendar

Last Earnings
5/15/2025
Today
8/01/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KTTA
CIK
1841330
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($10.60)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.90 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-88.14%
Return on Assets
-81.21%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.84
Quick Ratio
3.84

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.60 per share
Price / Book
0.07

Miscellaneous

Outstanding Shares
7,440,000
Free Float
7,243,000
Market Cap
$5.25 million
Optionable
Not Optionable
Beta
0.25

Social Links

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:KTTA) was last updated on 8/1/2025 by MarketBeat.com Staff
From Our Partners